Author/Authors :
Moreno، نويسنده , , Raْl and Fernلndez، نويسنده , , Maria Cristina Marino Calvo، نويسنده , , Luis and Sلnchez-Recalde، نويسنده , , Angel and Galeote، نويسنده , , Guillermo and Sanchez-Aquino، نويسنده , , Rosa and Alfonso، نويسنده , , Fernando and Macaya، نويسنده , , Carlos and Lَpez-Sendَn، نويسنده , , José L.، نويسنده ,
Abstract :
The only clinical benefit of drug-eluting stents (DESs) over bare metal stents (BMSs) is a significant decrease in the need for new revascularization procedures. We evaluated whether DESs also decrease the incidence of myocardial infarction at midterm. We performed a meta-analysis from 25 randomized trials comparing commercially available DESs with BMSs that included 9,791 patients overall. There was no heterogeneity across the trials included (Q test for heterogeneity, p = 0.68). Of the 9,791 patients included in all the trials, 364 developed an acute myocardial infarction during follow-up (6 to 12 months). The risk of myocardial infarction was significantly lower in patients allocated to DESs (3.3% vs 4.2% in those allocated to BMSs, odds ratio 0.79, 95% confidence interval 0.64 to 0.97, p = 0.03). In conclusion, the significant decrease in angiographic restenosis associated with the use of DESs leads not only to a decreased need for subsequent revascularization procedures but also a decreased incidence of myocardial infarction during the first 12 months after stent implantation.